BerGenBio ASA (OSL:BGBIO)
Norway
· Delayed Price · Currency is NOK 1.418
+0.034 (2.46%)
Jun 24, 2025, 9:31 AM CET
BerGenBio ASA Company Description
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat drug resistant, metastatic cancers, and immune-evasive in Norway.
The company’s lead clinical asset is the Bemcentinib (BGB016), an inhibitor of AXL receptor tyrosine kinase (AXL), which is in phase 1b/2a clinical trial to treat non-small cell lung cancer; and BGBIL025, a JAK2 inhibitor, which is in preclinical stage for treatment of the bone marrow disorder myelofibrosis.
BerGenBio ASA was incorporated in 2007 and is based in Bergen, Norway.
BerGenBio ASA
| Country | Norway |
| Founded | 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Olav Hellebo |
Contact Details
Address: Nygardsgaten 114 Bergen, 5008 Norway | |
| Phone | 47 55 96 11 59 |
| Website | bergenbio.com |
Stock Details
| Ticker Symbol | BGBIO |
| Exchange | Oslo Børs |
| Fiscal Year | January - December |
| Reporting Currency | NOK |
| ISIN Number | NO0010650013 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Olav Hellebo BBA, MBA | Chief Executive Officer |
| Rune Skeie | Chief Financial Officer |
| Cristina Oliva M.D. | Chief Medical Officer |
| Graham Morell | Head of IR |
| Dr. Akil Jackson | Medical Director |